Molecular mechanisms underlying oseltamivir resistance mediated by an I117V substitution in the neuraminidase of subtype H5N1 avian influenza a viruses

Journal of Infectious Diseases

Volumn 207, Issue 1, 2013, Pages 89-97

  Takano, Ryo ^a   Kiso, Maki ^a   Igarashi, Manabu ^d   Le, Quynh Mai ^e   Sekijima, Masakazu ^b   Ito, Kimihito ^d   Takada, Ayato ^d   Kawaoka, Yoshihiro ^a,c,f  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d HOKKAIDO UNIVERSITY   (Japan)

^e NATIONAL INSTITUTE OF HYGIENE AND EPIDEMIOLOGY   (Viet Nam)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

H5N1; I117V mutation; Influenza Avirus; Molecular dynamics simulation; Neuraminidase; Oseltamivir

Indexed keywords

ARGININE; CARBOXYL GROUP; ISOLEUCINE; OSELTAMIVIR; SIALIDASE; SIALIDASE INHIBITOR; VALINE;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVIAN INFLUENZA VIRUS; BINDING AFFINITY; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; GENE MUTATION; HYDROGEN BOND; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; VIRUS SURVIVAL;

ANIMALS; ANTIVIRAL AGENTS; BIRDS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; FEMALE; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; MOLECULAR DYNAMICS SIMULATION; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; POINT MUTATION; POULTRY; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84872981105     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis633     Document Type: Article

References (35)

1. Li KS, Guan Y, Wang J, et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 2004; 430:209-13.
2. World Health Organization. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. http://www. who.int/influenza/human- animal-interface/en/. Accessed 21 October 2012.
3. Ungchusak K, Auewarakul P, Dowell SF, et al. Probable person-toperson transmission of avian influenza A (H5N1). N Engl J Med 2005; 352:333-40.
4. Colman PM, Hoyne PA, Lawrence MC. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J Virol 1993; 67:2972-80.
5. Ives JA, Carr JA, Mendel DB, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002; 55:307-17.
6. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364:759-65.
7. de Jong MD, Tran TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza (H5N1) infection. N Engl J Med 2005; 353:2667-72.
8. Rameix-Welti MA, Agou F, Buchy P, et al. Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir. Antimicrob Agents Chemother 2006; 50:3809-15.
9. McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA. Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg Infect Dis 2007; 13:1354-7.
10. Monto AS, McKimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006; 50:2395-402.
11. Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG. Susceptibility to highly pathogenic A (H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res 2007; 73:228-31.
12. Ilyushina NA, Seiler JP, Rehg JE, Webster RG, Govorkova EA. Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets. PLoS Pathog 2010; 6:e1000933.
13. Yi H, Lee JY, Hong EH, et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus, South Korea. Emerg Infect Dis 2010; 16:1938-42.
14. Hurt AC, Leang SK, Speers DJ, Barr IG, Maurer-Stroh S. Mutations I117V and I117M and oseltamivir sensitivity of pandemic (H1N1) 2009 viruses. Emerg Infect Dis 2012; 18:109-12.
15. Case DA, Darden TA, Cheatham TE III, et al. AMBER 11. San Francisco: University of California, 2010.
16. Dolinsky TJ, Czodrowski P, Li H, et al. PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations. Nucleic Acids Res 2007; 35:W522-5.
17. Frisch MJ, Trucks GW, Schlegel HB, et al.. Gaussian 03, revision E.01. Wallingford, CT: Gaussian, 2004.
18. Bayly CI, Cieplak P, Cornell WD, Kollman PA. A well-behaved electrostatic potential based method using charge restraints for determining atom-centered charges: the RESP model. J Phys Chem 1993; 97:10269-80.
19. Wang J, Wang W, Kollman PA, Case DA. Automatic atom type and bond type perception in molecular mechanical calculations. J Mol Graph Model 2006; 25:247-60.
20. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C. Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 2006; 65:712-25.
21. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J Comput Chem 2004; 25:1157-74.
22. Berendsen HJC, Postma JPM, Funsteren WF. Molecular dynamics with coupling to an external bath. J Chem Phys 1984; 81:3684-90.
23. Ryckaert JP, Ciccotti G, Berendsen HJC. Numerical integration of the Cartesian equations of motion of a system with constraints: Molecular dynamics of n-Alkanes. J Comput Phys 1977; 23:327-41.
24. Darden T, York D, Pedersen L. Particle mesh Ewald: An N·log(N) method for Ewald sums in large systems. J Chem Phys 1993; 98:10089-92.
25. Masukawa KM, Kollman PA, Kuntz ID. Investigation of neuraminidase- substrate recognition using molecular dynamics and free energy calculations. J Med Chem 2003; 46:5628-37.
26. Aruksakunwong O, Malaisree M, Decha P, et al. On the lower susceptibility of oseltamivir to influenza neuraminidase subtype N1 than those in N2 and N9. Biophys J 2007; 92:798-807.
27. Malaisree M, Rungrotmongkol T, Nunthaboot N, et al. Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation. Amino Acids 2009; 37:725-32.
28. Wang NX, Zheng JJ. Computational studies of H5N1 influenza virus resistance to oseltamivir. Protein Sci 2009; 18:707-15.
29. Le QM, Ito M, Muramoto Y, et al. Pathogenicity of highly pathogenic avian H5N1 influenza A viruses isolated from humans from 2003 to 2008 in Northern Vietnam. J Gen Virol 2010; 91:2485-90.
30. Uhlendorff J, Matrosovich T, Klenk HD, Matrosovich M. Functional significance of the hemadsorption activity of influenza virus neuraminidase and its alteration in pandemic viruses. Arch Virol 2009; 154:945-57.
31. Srinivasan J, Cheatham TE III, Cieplak P, Kollman PA, Case DA. Continuum solvent studies of the stability of DNA, RNA, and phosphoramidate- DNA helices. J Am Chem Soc 1998; 120:9401-9.
32. Govorkova EA, Ilyushina NA, McClaren JL, Naipospos TS, Douangngeun B, Webster RG. Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. Antimicrob Agents Chemother 2009; 53:3088-96.
33. Luo G, Chung J, Palese P. Alterations of the stalk of the influenza virus neuraminidase: deletions and insertions. Virus Res 1993; 29:141-53.
34. Mitnaul LJ, Castrucci MR, Murti KG, Kawaoka Y. The cytoplasmic tail of influenza A virus neuraminidase (NA) affects NA incorporation into virions, virion morphology, and virulence in mice but is not essential for virus replication. J Virol 1996; 70:873-9.
35. Yen HL, Monto AS, Webster RG, Govorkova EA. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis 2005; 192:665-72.